Results 101 to 110 of about 25,852 (233)

P2Y12 Inhibitor Monotherapy After Short DAPT in Acute Coronary Syndrome: A Systematic Review and Meta-analysis. [PDF]

BACKGROUND P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) may balance ischemic and bleeding risks in patients with acute coronary syndrome (ACS).
Gragnano, Felice, Capodanno, Davide, Spagnolo, Marco, Laudani, Claudio, Mattia Galli, Galli, Mattia, Marco Spagnolo, Marco Valgimigli, Davide Capodanno, Occhipinti, Giovanni, D'Amario, Domenico, Navarese, Eliano Pio, Giovanni Occhipinti, Roxana Mehran, Domenico D'Amario, Felice Gragnano, Mehran, Roxana, Valgimigli, Marco, Angiolillo, Dominick J, Dominick J Angiolillo, Claudio Laudani, Eliano Pio Navarese   +21 more
core   +1 more source

P2Y12 Platelet Function Assay for Assessment of Bleeding Risk in Coronary Artery Bypass Grafting [PDF]

, 2014
Background The use of platelet function testing has been advocated to individualize the time needed between discontinuation of P2Y12 inhibitors and coronary artery bypass grafting (CABG).
Dellis, S. L., Hartman, A. R., Yu, P. J., Cassiere, H. A., Stein, J., Manetta, F.   +5 more
core   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

ALOX15 links lipid metabolism to receptor trafficking in platelet activation

The FEBS Journal, EarlyView.
This schematic summarizes known and newly identified mechanisms of thrombin‐mediated platelet activation. In addition to classical thrombin‐induced PAR4 signaling pathways, thrombin activates an ALOX15–HETE–PKCθ–NMT1 signaling cascade that promotes protein myristoylation, facilitates receptor trafficking, and enhances PAR4 surface expression on ...
Yosef Eshetie Amare, Sharad Saxena, Serena Zacchigna   +2 more
wiley   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors

Journal of Atherosclerosis and Thrombosis, 2018
In percutaneous coronary intervention (PCI)-treated acute coronary syndrome (ACS) patients on clopidogrel therapy, high on-treatment platelet adenosine diphosphate (ADP) reactivity was observed in numerous studies, with significant increases in non-fatal myocardial infarction, definite/probable stent thrombosis, or cardiovascular mortality. Compared to
Ristorto, Jessica, Messas, Nathan, Marchandot, Benjamin, Kibler, Marion, Hess, Sébastien, Meyer, Nicolas, Schaeffer, Michael, Tuzin, Nicolas, Ohlmann, Patrick, Jesel, Laurence, Morel, Olivier   +10 more
openaire   +3 more sources

Anti-platelet therapy: ADP receptor antagonists. [PDF]

, 2011
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis.
Heptinstall, S, Wijeyeratne, YD, Stan Heptinstall, Yanushi Dullewe Wijeyeratne   +3 more
core   +1 more source

Investigator‐Led Research to Improve the Diagnostic Assessment of Platelet Function Disorders: Reflections on the Challenges and Rewards

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Investigator‐led research and quality improvement initiatives have led to important improvements in the diagnostic assessment of platelet function disorders (PFD). Methods Personal reflections were used to summarize our contributions to knowledge on PFD diagnostic assessment, pathogenesis, and bleeding risks.
Catherine P. M. Hayward
wiley   +1 more source

Testing for Non‐Severe Heritable Platelet Function Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Heritable platelet function disorders (HPFD) are a diverse group of bleeding disorders characterised by a primary qualitative defect in platelet function rather than platelet number. HPFD may be broadly categorised according to the severity of bleeding, with Glanzmann thrombasthenia and Bernard Soulier syndrome classically considered severe ...
Kate Burley, Naomi Cornish, Maria Molina Carretero, Sarah K. Westbury   +3 more
wiley   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source